FDA Alerts
FDA Gives Green Light to Ramucirumab in Combination with Paclitaxel
On November 5, 2014, the U. S. Food and Drug Administration approved ramucirumab (Cyramza, Eli Lilly and Company) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
FDA approves Erbitux to treat late-stage head and neck cancer
The U.S. Food and Drug Administration today approved Erbitux ( cetuximab ) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.
FDA Drug Safety Communication: Bisphosphonates and Esophageal Cancer
The U.S. Food and Drug Administration (FDA) is continuing to review data from published studies to evaluate whether use of oral bisphosphonate drugs is associated with an increased risk of cancer of the esophagus (esophageal cancer).